A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder

Journal of Affective Disorders

Volumn 54, Issue 1-2, 1999, Pages 39-48

  Chouinard, Guy ^a   Saxena, Bishan ^b   Bélanger, Marie Claire ^a   Ravindran, Arun ^c   Bakish, David ^c   Beauclair, Linda ^a   Morris, Paul ^d   Nair, N P Vasavan ^e   Manchanda, Rahul ^f   Reesal, Robin ^g   Remick, Ronald ^h   O'Neill, M Colleen ⁱ  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b Hamilton Psychiatric Hospital   (Canada)

^c ROYAL OTTAWA HOSPITAL   (Canada)

^d Aberfoyle Clinic   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g BOVAR Western Research   (Canada)

^h ST PAUL S HOSPITAL   (Canada)

ⁱ SmithKline Beecham Pharma   (Canada)

Author keywords

Antianxiety; Antidepressant; Anxiety; Depression; Fluoxetine; Paroxetine; SSRIs

Indexed keywords

FLUOXETINE; PAROXETINE;

AKATHISIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; HUMAN; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PREMATURE EJACULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; TRANQUILIZING ACTIVITY; TREMOR;

ADULT; ANXIETY; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOXETINE; HUMANS; MALE; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0033061679     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(98)00188-8     Document Type: Article

References (32)

1. Bascara, L., 1989. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Curr Ther Res 46, 815-820.
2. Bignamini, A., Rapisarda, V., 1992. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients (Italian paroxetine study group). Int Clin Psychopharmacol 6 (suppl 4), 37-41.
3. Boyer, W.F., Blumhardt, C.L., 1992. The safety profile of paroxetine. J Clin Psychiatry 2 (suppl), 61-66.
4. Boyer, W.F., Feighner, J.P., 1991. Side effects of the selective serotonin reuptake inhibitors. In: Feighner, J.P., Boyer, W.F., (Eds). Selective Serotonin Reuptake Inhibitors. John Wiley and Sons, Chichester, U.K., pp. 133-152.
5. Chouinard, G., Ross-Chouinard, A., Annable, L., Mercier, P., 1980. The extrapyramidal symptom rating scale. Can J Neurol Sci 7, 233.
6. Chouinard, G., Sultan, S., 1992. A case of Parkinson's disease exacerbated by fluoxetine. Human Psychopharmacol 7, 63-66.
7. Chouinard, G., 1985. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry 47, 32-37.
8. Clark, R.N., Ashby, Jr. C.R., Dewey, S.L., Ramachandran, P.V., Strecker, R.E., 1996. Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat. Synapse 23, 125-131.
9. Cohn, J.B., Wilcox, C.S., 1992. Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 53 (2, suppl), 52-56.
10. Cohn, J.B., Crowder, J.E., Wilcox, C.S., Ryan, P.J., 1990. A placebo and imipramine controlled study of paroxetine. Psychopharmacol Bull 26, 185-189.
11. De Wilde, J., Spiers, R., Mertens, C., Bartholomé, F., Schotte, G., Leyman, S., 1993. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 87, 141-145.
12. Dunbar, G.C., Fuell, D.L., 1990. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 6 (suppl 4), 81-90.
13. Dunbar, G.C., Cohn, J.B., Fabre, L.F., Feighner, J.P., Fieve, R.R., Mendels, J., Shrivastava, R.K., 1991. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 159, 394-398.
14. Dunner, D.L., Cohn, J.B., Walshe, III T., Cohn, C.K., Feighner, J.P., Fieve, R.R., Halikas, J.P., Hartford, J.T., Hearst, E.D., Settle, Jr. E.G., Menolascino, F.J., Muller, D.J., 1992. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 53 (suppl), 57-60.
15. Gardier, A.M., Lepoul, E., Trouvin, J.H., Chanut, E., Dessalles, M.C., Jacquot, C., 1994. Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci 54, PL51-56.
16. Gorman, J.M., Liebowitz, M.R., Fyer, A.J., Goetz, D., Campeas, R.B., Fyer, M.R., Davies, S.O., Klein, D.F., 1987. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 7, 329-332.
17. Hamilton, M., 1960. A rating scale for depression. J Neurosurg Psychiatry 12, 56-62.
18. Huitfeldt, B., Montgomery, S.A., 1983. Comparison between zimelidine and amitriptyline of efficacy and adverse symptoms. Acta Psychiatr Scand 69 (suppl 308), 55-69.
19. Hutchinson, D.R., Tong, S., Moon, C.A., Vince, M., Clarke, A., 1992. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol 6 (suppl 4), 43-51.
20. Leo, R.J., 1996. Movement disorders associated with the serotonin reuptake inhibitors. J Clin Psychiatry 57, 449-454.
21. Lipinski, Jr. J.F., Mallya, G., Zimmerman, P., Pope, Jr. H.G., 1989. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 50, 339-342.
22. Mertens, C., Pintens, H., 1988. Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin. Acta Psychiatr Scand 77, 683-688.
23. Montgomery, S.A., Henry, J., McDonald, G., Dinan, T., Lader, M., Hindmarch, I., Clare, A., Nutt, D., 1994. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9, 47-53.
24. Noguera, R., Altuna, R., Alvarez, E., Ayuso, J.L., Casais, L., Udina, C., 1991. Fluoxetine versus clomipramine in depressed patients: a controlled multicentre trial. J Affect Disord 22, 119-124.
25. Prozac (fluoxetine) product monograph, 1996. Eli Lilly and Co., Indianapolis, Indiana.
26. Schöne, W., Ludwig, M., 1993. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J CHn Psychopharmacol 13 (suppl 2), 34S-39S.
27. Sheehan, D., Dunbar, G.C., Fuell, D.L., 1992. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacol Bull 28, 139-143.
28. Spielberger, C.D., Gorsuch, R.L., Lushene, R.E., 1970. The State-Trait Anxiety Inventory Test manual. Consulting Psychologists Press, Palo Alto, CA.
29. Thomas, D.R., Nelson, D.R., Johnson, A.M., 1987. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93, 193-200.
30. Tignol, J., 1993. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 13 (6, suppl 2), 18S-22S.
31. Tulloch, I.F., Johnson, A.M., 1992. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 53 (2, suppl), 7-12.
32. Zitrin, C.M., Klein, D.F., Woerner, M.G., Ross, D.C., 1983. Treatment of phobias. I: Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 40, 125-138.